Login to Your Account

AC Immune Drops ACI-91 on Phase II Alzheimer's Failure

By Cormac Sheridan
Staff Writer

Wednesday, February 6, 2013
The drug development graveyard that is Alzheimer's disease has claimed yet another victim. This time it's AC Immune SA's ACI-91, a drug that had offered a new approach to tackling this most intractable of diseases.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription